Phase 2 Migraine Trial, Recruiting NCT07646613 Sponsor: Aspeya, Inc. Condition: Migraine
Back to Migraine

Phase 2 Migraine Trial, Recruiting

NCT07646613
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand what the study involves and are willing to sign a written consent form
  • People aged 18 to 65 years old at the time of screening
  • People with a Body Mass Index (BMI) between 18.5 and 35 at the time of screening
  • People who have a documented history of migraine (with or without aura) for at least one year, diagnosed according to recognised international headache guidelines
  • Female participants who are either unable to become pregnant, or who are able to become pregnant and agree to use contraception methods required by the study

Who may not be able to join:

  • People who have been diagnosed with any headache condition other than migraine
  • People with a current or past diagnosis of coronary artery disease (a condition affecting blood flow to the heart)
  • People with a history or current diagnosis of coronary artery spasms, serious irregular heartbeats, or conditions affecting blood flow to the limbs or organs (such as Raynaud's syndrome, angina, or a previous heart attack)
  • People who have had heart procedures, heart surgery, a serious blood infection (sepsis), or vascular surgery
  • People with a history or current diagnosis of conditions affecting the brain's blood supply, including stroke, mini-stroke (TIA), or bleeding in or around the brain
  • People with a known or current mental health or psychological condition that, in the trial doctor's view, could affect their participation or safety — this may include conditions such as depression, psychosis, bipolar disorder, dementia, or substance misuse
  • People who have a known allergy, sensitivity, or medical reason to avoid DHE, other ergot-based medications, or any ingredient in the study treatment
  • People who have taken certain medications that strongly or moderately affect how the body processes drugs (known as CYP3A4 inhibitors or inducers) within a specified period before joining the trial (confirm with trial site)
  • People who have any other significant health condition at screening — such as conditions affecting the nervous system, heart, lungs, kidneys, liver, or digestive system — that in the trial doctor's view could affect safety or study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +41 76 358 88 30

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Aspeya, Inc.
Registry
ClinicalTrials.gov
Start date
19 May 2026
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of patients with freedom from headache pain at 2 hours post-dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov